User:Mr. Ibrahem/Entrectinib

Entrectinib, sold under the brand name Rozlytrek, is a medication used to treat non-small cell lung cancer (NSCLC) which are ROS1-positive or solid tumors that are NTRK fusion-positive. It is taken by mouth.

Common side effects include tiredness, constipation, change in taste, swelling due to fluid retention, dizziness, diarrhea, nausea, numbness, difficulty breathing, increased weight, cough, fever, thinking problems, and vision problems. Other side effects include heart failure, bone fractures, liver problems, high uric acid, and QT prolongation. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1), and anaplastic lymphoma kinase (ALK).

Entrectinib was approved for medical use in the United States in 2019, and Australia and Europe in 2020. In the United Kingdom a month of treatment costs the NHS about £5,200 as of 2021. This amount in the United States costs about 16,800 USD.